Interleukin 35 Polymorphisms Are Associated with Decreased Risk of Premature Coronary Artery Disease, Metabolic Parameters, and IL-35 Levels: The Genetics of Atherosclerotic Disease (GEA) Study

Table 3

Association between EBI3 and IL-12A gene polymorphisms and premature coronary artery disease.

Polymorphism	Genotype frequency (%)			MAF	Model	OR [95% CI]
(i) EBI3
rs428253	G>C
	GG	GC	CC
Control ()	536 (0.614)	277 (0.317)	60 (0.069)	0.227	Additive	0.831 [0.699–0.988]	0.036
					Dominant	0.842 [0.681–1.042]	0.115
					Recessive	0.614 [0.392–0.963]	0.033
pCAD ()	740 (0.637)	371 (0.319)	51 (0.044)	0.204	Heterozygote	0.935 [0.750–1.167]	0.553
					Codominant 1	0.895 [0.715–1.120]	0.334
					Codominant 2	0.591 [0.375–0.933]	0.027
(ii) IL-12A
rs2243115	T>G
	TT	TG	GG
Control ()	746 (0.855)	120 (0.137)	7 (0.008)	0.077	Additive	0.674 [0.499–0.909]	0.010
					Dominant	0.676 [0.494–0.925]	0.014
					Recessive	0.294 [0.048–1.785]	0.183
pCAD ()	1048 (0.902)	112 (0.096)	2 (0.002)	0.050	Heterozygote	0.698 [0.508–0.956]	0.027
					Codominant 1	0.694 [0.505–0.954]	0.024
					Codominant 2	0.282 [0.046–1.712]	0.169

Models were adjusted for age, gender, body mass index, current smoking status, alanine aminotransferase, aspartate aminotransferase, and uric acid. Models were adjusted for age, gender, body mass index, and current smoking status. Italic numbers indicate significant associations. The control group subjects were normoglycaemic nondiabetic. MAF: minor allele frequency; pCAD: premature coronary artery disease.
Only the significant associated polymorphisms are shown.